Intraepithelial neoplasia

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Wednesday, March 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

Cervical Intraepithelial Neoplasia Pipeline Review - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 7, 2020
Women, Consumer, Health, Pharmaceutical, Oncology, Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Gynaecological cancer, Clinical medicine, Medical specialties, Health

The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Cervical Intraepithelial Neoplasia (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (Women's Health) pipeline depth and focus of Indication therapeutics.

Cervical Intraepithelial Neoplasia, Pipeline Review, H2 2019 - Bioleaders Corp, Elicio Therapeutics, Novan Inc & Vaccibody AS - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 14, 2020
Health, Pharmaceutical, Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Gynaecological cancer, Health, Clinical medicine, Medicine, Papillomavirus, Vaccines

The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

Retrieved on: 
Monday, November 25, 2019
Medical specialties, Medicine, Branches of biology, Immune system, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cancer immunotherapy, T cell

Details for the presentation are below:

Key Points: 
  • Details for the presentation are below:
    The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways.
  • The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients.
  • PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors.

Global Pancreatic Cancer Market to 2026 - Advancement of Technology in Therapeutic Devices and Expanding Prevalence of Cancer Growth

Retrieved on: 
Wednesday, October 2, 2019
RTT, Pancreatic cancer, Pancreatic duct, Pancreas, Cancer, Intraepithelial neoplasia

DUBLIN, Oct. 2, 2019 /PRNewswire/ -- The "Pancreatic Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 2, 2019 /PRNewswire/ -- The "Pancreatic Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pancreatic Cancer market accounted for $1,904.20 million in 2017 and is expected to reach $4,728.19 million by 2026 growing at a CAGR of 10.6% during the forecast period.
  • Advancement of technology in therapeutic devices and expanding prevalence of cancer growth are the factors driving the market.
  • Most Pancreatic Cancers arise from microscopic non-invasive epithelial proliferations within the pancreatic ducts, referred to as pancreatic intraepithelial neoplasias.

PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data

Retrieved on: 
Tuesday, October 1, 2019
Cancer, Infectious causes of cancer, Papillomavirus, RTT, Vaccines, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Cervarix, HspE7

BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced it will prioritize clinical development of PDS0101 in advanced cancers following its recent reporting of promising PDS0101 Phase 1 clinical trial outcome data.
  • On September 19, 2019, PDS reported clinical outcome data from a Phase 1 clinical trial of PDS0101 in patients with cervical intraepithelial neoplasia (CIN) infected with multiple high-risk, cancer-causing types of human papillomavirus (HPV).
  • Our intent is to continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers.
  • This approach has been recently supported by promising Phase 1 clinical outcome data, said Dr. Frank Bedu-Addo, CEO of PDS.

Novan Awarded Approximately $1.1 Million Grant by Department of Defense

Retrieved on: 
Friday, September 20, 2019
Infectious causes of cancer, Health, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, National Institutes of Health, Articles, Vaccines

The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.

Key Points: 
  • The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.
  • This grant is in addition to the previously announced National Institute of Health (NIH) Phase 1 grant of approximately $223,000 for the development of a separate product candidate (WH602).
  • Both product candidates will represent core initiatives within the previously announced Novan womens health business unit.
  • The views expressed in this press release are those of the Company and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Novan Advances Women’s Health Business Unit with Non-Dilutive Funding

Retrieved on: 
Wednesday, August 14, 2019
Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Health, Clinical medicine

These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).

Key Points: 
  • These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).
  • Prospectively, Novan expects to be eligible to receive additional grant dollars for Phase 2 and 3 extensions.
  • Both product candidates will represent the core to Novans womens health business unit.
  • This unit will continue to be supported through a collaboration with Health Decisions, Inc. (Health Decisions).